INS and Insulin resistance: Our study showed that the late-phase insulin levels decreased after ELX/TEZ/IVA therapy initiation—an effect we interpret as insulin-resistance-improvement: less insulin is needed for lower glucose levels, and the initial insulin secretion is sufficient.